Latest Period
Q1 2026
Security Snapshot
Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) Institutional Ownership
CUSIP: 03843E104
13F Institutional Holders and Ownership History from Q3 2018 to Q1 2026
Institutions Reporting
178
Shares (Excl. Options)
71,677,682
Price
$4.15
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.001 par value
- Symbol
- AQST on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 71,677,682
- Total 13F value
- $297,464,470
- Portfolio coverage rank
- 0%
- Share change
- +7,541
- Value change
- -$19,848,458
- Number of holders
- 178
- Shares outstanding
- 120,192,308
- SEC-reported price per share
- $4.02
- Insider filing price
- $4.02
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- AQST - Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value is tracked under CUSIP 03843E104.
- 178 institutions reported positions in Q1 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 178 to 178 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $466,378,990 to $297,464,470.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 178 institutions filings for Q1 2026.
Security key
03843E104
Latest holder period
Q1 2026
13F holders
178
13D/G owners
4
CIK / CUSIP context first
Open Q1 2026 holders
AQST full holder history
Aquestive Therapeutics, Inc. SEC filings
Aquestive Therapeutics, Inc. company facts
Aquestive Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 03843E104:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
AQST
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BRATTON DOUGLAS K | 11% | $28,720,687 | 10,077,434 | BRATTON DOUGLAS K | 31 Dec 2024 | |||
| BlackRock, Inc. | 5.3% | $35,923,900 | 6,426,343 | BlackRock, Inc. | 30 Sep 2025 | |||
| RTW INVESTMENTS, LP | 5.2% | $34,937,500 | 6,250,000 | RTW Investments, LP | 30 Sep 2025 | |||
| Venrock Healthcare Capital Partners III, L.P. | 2.9% | $7,494,890 | 2,629,786 | Venrock Healthcare Capital Partners III, L.P. | 31 Dec 2024 |
As of 31 Mar 2026, 178 institutional investors reported holding 71,677,682 shares of Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST). This represents 60% of the company’s total 120,192,308 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
50%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Bratton Capital Management, L.P. | 8.2% | 9,810,958 | 0% | 100% | $40,715,476 |
| BlackRock, Inc. | 6.2% | 7,509,071 | -3.4% | 0% | $31,162,644 |
| RTW INVESTMENTS, LP | 6.2% | 7,426,471 | +19% | 0.31% | $30,819,855 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.7% | 4,443,698 | 0% | 0% | $18,441,347 |
| FEDERATED HERMES, INC. | 2.4% | 2,940,339 | +45% | 0.02% | $12,202,407 |
| Balyasny Asset Management L.P. | 2.4% | 2,900,570 | +199% | 0.02% | $12,037,366 |
| STATE STREET CORP | 2.1% | 2,546,191 | +3.4% | 0% | $10,566,693 |
| SAMSARA BIOCAPITAL, LLC | 2.1% | 2,500,000 | 0% | 1% | $10,375,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 2,408,191 | +1.7% | 0% | $9,996,351 |
| BANK OF AMERICA CORP /DE/ | 2% | 2,405,050 | +99% | 0% | $9,980,958 |
| Sio Capital Management, LLC | 1.6% | 1,922,887 | +94% | 1.2% | $7,979,981 |
| MORGAN STANLEY | 1.3% | 1,591,792 | -9.5% | 0% | $6,605,938 |
| Blue Owl Capital Holdings LP | 1.1% | 1,347,932 | +157% | 1.5% | $5,593,918 |
| TWO SIGMA INVESTMENTS, LP | 0.95% | 1,139,404 | +199% | 0% | $4,728,527 |
| Janney Montgomery Scott LLC | 0.91% | 1,089,110 | -0.38% | 0.01% | $4,520,000 |
| COMMONWEALTH EQUITY SERVICES, LLC | 0.9% | 1,082,680 | +6.2% | 0.01% | $4,493,124 |
| WELLS FARGO & COMPANY/MN | 0.86% | 1,034,644 | -13% | 0% | $4,293,773 |
| JANE STREET GROUP, LLC | 0.86% | 1,030,050 | +101% | 0% | $4,274,707 |
| WASATCH ADVISORS LP | 0.73% | 878,316 | +29% | 0.02% | $3,645,011 |
| BNP PARIBAS FINANCIAL MARKETS | 0.67% | 809,007 | 0% | 0% | $3,357,379 |
| BARCLAYS PLC | 0.66% | 799,163 | +134% | 0% | $3,316,526 |
| NORTHERN TRUST CORP | 0.61% | 732,504 | -1.4% | 0% | $3,039,892 |
| Propel Bio Management, LLC | 0.59% | 710,988 | 1.9% | $2,950,600 | |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.58% | 691,750 | 0% | 0% | $2,870,763 |
| VANGUARD FIDUCIARY TRUST CO | 0.53% | 637,512 | 0% | 0% | $2,645,675 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
31
Latest
Q1 2026
Rows shown
1-25 of 31
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 71,677,682 | $297,464,470 | -$19,848,458 | $4.15 | 178 |
| 2025 Q4 | 72,216,999 | $466,378,990 | +$34,098,128 | $6.46 | 178 |
| 2025 Q3 | 66,072,635 | $369,385,999 | +$106,443,073 | $5.59 | 151 |
| 2025 Q2 | 47,601,655 | $157,593,347 | +$12,692,456 | $3.31 | 115 |
| 2025 Q1 | 44,051,858 | $127,751,552 | -$2,587,459 | $2.90 | 120 |
| 2024 Q4 | 43,378,481 | $154,428,036 | -$13,648,629 | $3.56 | 113 |
| 2024 Q3 | 46,754,842 | $232,438,651 | +$19,226,897 | $4.98 | 116 |
| 2024 Q2 | 42,397,820 | $110,236,742 | -$9,111,350 | $2.60 | 95 |
| 2024 Q1 | 41,491,141 | $176,751,489 | +$88,086,384 | $4.26 | 96 |
| 2023 Q4 | 23,788,793 | $48,053,747 | +$1,931,780 | $2.02 | 57 |
| 2023 Q3 | 13,082,950 | $20,018,501 | +$5,799,587 | $1.53 | 45 |
| 2023 Q2 | 19,076,504 | $31,486,971 | +$6,895,297 | $1.65 | 54 |
| 2023 Q1 | 14,936,175 | $17,026,675 | +$181,515 | $1.14 | 34 |
| 2022 Q4 | 14,914,775 | $13,452,963 | -$924,306 | $0.90 | 34 |
| 2022 Q3 | 15,885,912 | $18,581,000 | -$701,258 | $1.17 | 41 |
| 2022 Q2 | 16,697,754 | $10,681,727 | -$1,110,269 | $0.64 | 37 |
| 2022 Q1 | 15,540,728 | $40,562,854 | -$1,905,712 | $2.61 | 49 |
| 2021 Q4 | 16,159,821 | $62,860,046 | +$1,542,125 | $3.89 | 50 |
| 2021 Q3 | 14,777,244 | $64,430,510 | -$3,394,828 | $4.36 | 44 |
| 2021 Q2 | 15,624,060 | $62,031,877 | -$6,395,474 | $3.97 | 56 |
| 2021 Q1 | 16,607,064 | $86,353,974 | -$13,347,120 | $5.20 | 62 |
| 2020 Q4 | 19,140,719 | $102,400,992 | -$3,894,598 | $5.35 | 65 |
| 2020 Q3 | 19,883,853 | $96,529,634 | +$6,732,727 | $4.85 | 57 |
| 2020 Q2 | 18,511,676 | $89,959,616 | +$16,355,927 | $4.86 | 56 |
| 2020 Q1 | 15,971,551 | $35,033,099 | -$11,294,638 | $2.19 | 42 |